نتایج جستجو برای: tnbcs

تعداد نتایج: 265  

2013
Luciano Cascione Pierluigi Gasparini Francesca Lovat Stefania Carasi Alfredo Pulvirenti Alfredo Ferro Hansjuerg Alder Gang He Andrea Vecchione Carlo M. Croce Charles L. Shapiro Kay Huebner

Triple negative breast cancer (TNBC) is a heterogeneous disease at the molecular, pathologic and clinical levels. To stratify TNBCs, we determined microRNA (miRNA) expression profiles, as well as expression profiles of a cancer-focused mRNA panel, in tumor, adjacent non-tumor (normal) and lymph node metastatic lesion (mets) tissues, from 173 women with TNBCs; we linked specific miRNA signatures...

2014
Diego Caliari Valentina Zappulli Roberta Rasotto Barbara Cardazzo Federica Frassineti Michael H Goldschmidt Massimo Castagnaro

BACKGROUND Human breast cancer is a heterogeneous disease classified by molecular subtyping into luminal A, luminal B, HER2-overexpressing, basal-like, claudin-low and normal-breast like. The routinely applied and standardized immunohistochemical-based surrogates of this classification group together the last three entities as triple-negative breast cancer (TNBCs) that show the most diverse and...

Journal: :Cancer discovery 2012
Yasir H Ibrahim Celina García-García Violeta Serra Lei He Kristine Torres-Lockhart Aleix Prat Pilar Anton Patricia Cozar Marta Guzmán Judit Grueso Olga Rodríguez Maria Teresa Calvo Claudia Aura Orland Díez Isabel T Rubio José Pérez Jordi Rodón Javier Cortés Leif W Ellisen Maurizio Scaltriti José Baselga

UNLABELLED PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would result in HR impairment and subsequent sensitization to PARP inhibitors. We show in TNBC ce...

2017
Bushra Sikandar Muhammad Asif Qureshi Saima Naseem Saeed Khan Talat Mirza

Background: Patients with triple negative breast cancer (TNBC) have limited therapeutic options, largely because the complex tumour environment is not well-characterized. These patients are potential, but largely un-fathomed, candidates for immunotherapy. It is therefore highly relevant to characterize leukocyte complexity in TNBCs. Objective: To investigate leukocyte complexity in tumour envir...

2016
Pawel Domagala Jolanta Hybiak Janusz Rys Tomasz Byrski Cezary Cybulski Jan Lubinski

Pathologic complete response (pCR) after neoadjuvant chemotherapy is considered a suitable surrogate marker of treatment efficacy in patients with triple-negative breast cancers (TNBCs). However, the molecular mechanisms underlying pCR as a result of such treatment remain obscure. Using real-time PCR arrays we compared the expression levels of 120 genes involved in the main mechanisms of DNA re...

Journal: :international journal of hematology-oncology and stem cell research 0
mehrzad mirzania mehrzad mirzania md, hematology and medical oncology department, cancer research center , cancer institute of iran, imam khomeini hospital complex, tehran university of medical sciences(tums).

triple negative breast cancers (tnbcs) are associated with aggressive course, higher rates of visceral and central nervous system metastases and lower survival rate than hormone receptor positive. once metastasis has occurred, a median survival was approximately one year. currently, chemotherapy in tnbc is similar to other her2- negative breast cancers but in the near future, it will revolution...

2012
Swati Kulkarni Katarzyna Augoff Louis Rivera Brian McCue Thaer Khoury Adrienne Groman Li Zhang Lili Tian Khalid Sossey-Alaoui

BACKGROUND Breast Cancer (BC) is a heterogeneous disease comprised of at least five genetically distinct subtypes, which together form the second leading cause of cancer death in women in the United States. Within BC subtypes, those classified as Triple Negative BCs (TNBCs) exhibit dismal survival rates due to their propensity to develop distant metastases. We have identified the WAVE3 protein,...

2017
Iram Fatima Ikbale El-Ayachi Ling Taotao M Angeles Lillo Raya Krutilina Tiffany N Seagroves Tomasz W Radaszkiewicz Miroslav Hutnan Vitezslav Bryja Susan A Krum Fatima Rivas Gustavo A Miranda-Carboni

Metastatic breast cancer is the leading cause of worldwide cancer-related deaths among women. Triple negative breast cancers (TNBC) are highly metastatic and are devoid of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) amplification. TNBCs are unresponsive to Herceptin and/or anti-estrogen therapies and too often become highly chemoresista...

2015
Jenny G. Parvani Gangarao Davuluri Michael K. Wendt Christine Espinosa Maozhen Tian David Danielpour Khalid Sossey-Alaoui William P. Schiemann

Transforming growth factor-β (TGF-β) functions to suppress tumorigenesis in normal mammary tissues and early-stage breast cancers and, paradoxically, acts to promote the metastasis and chemoresistance in late-stage breast cancers, particularly triple-negative breast cancers (TNBCs). Precisely how TGF-β acquires oncogenic characteristics in late-stage breast cancers remains unknown, as does the ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید